# D3 Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/d3-bio

- Industry: Biotechnology
- Headquarters: Wuxi, China
- Website: www.d3bio.com/
- Total disclosed funding: $370M
- Latest round: Series B (Dec 10, 2025)
- Investors on record: 9

## About

Founded in 2020 and based in Wuxi, China, D3 Bio (Wuxi) Co., Ltd., trading as D3 Bio, Inc., is a biotechnology company that researches and develops therapies for tumors and immune precision. George Chen, the company's CEO, has held senior global management positions in research, drug development and administration at leading institutions such as the National Institutes of Health, and multinational pharmaceutical companies such as Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pepperl+Gene and AstraZeneca. In December 2025, the firm raised USD 108 million in series B funding.

The company develops targeted therapies for cancer and immune-related diseases, including programs advancing into clinical evaluation across major markets. Its pipeline includes candidates designed to address tumor-driving mutations and immune pathways. 

The company generates revenue  from out-licensing agreements, milestone payments and commercialization of approved therapeutics.

The company plans to accelerate global Phase III clinical studies for its lead candidate and expand development across its oncology and immunology programs.

## Funding rounds

- Series B, Dec 10, 2025, $108M — Hong Shan, Temasek Holdings, IDG Capital, Medicxi, MPC, Wuxi AppTec Group, Shanghai Songqing Private Equity Fund Management
- Series A, Apr 7, 2024, $62M — Medicxi, MPC, Wuxi AppTec Group
- Series A, Nov 17, 2020, $200M — Hong Shan, Temasek Holdings, Boyu Capital, MPC, Shanghai AppTec

## Investors

- Hong Shan — Series A, Series B
- Temasek Holdings — Series A, Series B
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series A
- MPC — Series A, Series B
- Shanghai AppTec — Series A
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series A, Series B
- Wuxi AppTec Group — Series A, Series B
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B
- Shanghai Songqing Private Equity Fund Management — Series B